Log in

Keryx Biopharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 12/12/2018)
Today's Range
Now: $3.36
50-Day Range N/A
52-Week Range
Now: $3.36
Volume2.60 million shs
Average Volume1.69 million shs
Market Capitalization$344.00 million
P/E RatioN/A
Dividend YieldN/A
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Read More
Keryx Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.04 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KERX



Sales & Book Value

Annual Sales$60.64 million
Book Value($0.12) per share


Net Income$-163,440,000.00


Market Cap$344.00 million
Next Earnings DateN/A

Receive KERX News and Ratings via Email

Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions

What stocks does MarketBeat like better than Keryx Biopharmaceuticals?

Wall Street analysts have given Keryx Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Keryx Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analyst estimates of $29.56 million.
View Keryx Biopharmaceuticals' earnings history

Who are some of Keryx Biopharmaceuticals' key competitors?

What other stocks do shareholders of Keryx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Akebia Therapeutics (AKBA), 589378 (ARIA), Chesapeake Energy (CHKAQ) and Celldex Therapeutics (CLDX).

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the following people:
  • Ms. Jodie Pope Morrison, Interim CEO & Director (Age 43)
  • Mr. Scott A. Holmes, CFO, Sr. VP & Treasurer (Age 44)
  • Ms. Christine A. Carberry, Sr. VP & COO (Age 57)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Tony Chambers, VP of Sales

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

What is Keryx Biopharmaceuticals' stock price today?

One share of KERX stock can currently be purchased for approximately $3.36.

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $344.00 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

What is Keryx Biopharmaceuticals' official website?

The official website for Keryx Biopharmaceuticals is www.keryx.com.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.